thermo fisher result look solid underli organ growth headlin adj data center outag
impact inher move part prior quarter punch-lin remain
compani continu execut well post peer-lead growth led quarterli beat flow full-year
guidanc rais specif thermo fisher post organ grow th comp compani note face
impact data center outag notifi investor hich built forecast
previous ith preview link thermo fisher deliv revenu billion y/i
repres top line beat beat entir driven organ grow th hich better apples-
to-appl expect margin came modestli forecast op margin vs forecast possibl
mix segment strong lss off-set data center impact ai impact result adj ep beat expect
beat consensu beat unclear mani analyst proactiv
updat model data center outag line item ere modestli better forecast ad
quarter notabl compani tax rate vs model expens forecast
growth less broad-bas across segment seen prior quarter believ thermo fisher perform
consist expect life scienc solut lss came stronger expect organ grow th model
organ grow th believ improv result benefit strength
bioproduct consist ith result post peer analyt instrument ai deliv headlin organ grow th hich
miss model attribut miss aforement data center outag put impact lp segment
base media report though thermo fisher note releas primarili impact total
compani impact ould impli segment impact impli underli ai segment grow th ould beaten
forecast underli upsid reassur capit budget remain solid look addit color product
categori cryo-em mass spectrometry/chromatographi confer call hich believ contribut share
gain compani lab product servic lp post organ grow th versu model though actual
modestli prior estim place data center outag segment ell look confer call
 hether time may impact segment result check show end market fund channel
thermo fisher biopharma servic busi appear healthi final specialti diagnost sd organ grow th slow ed
 hich miss forecast specialti diagnost segment thermo fisher low estimate grow er recent year
 continu see opportun ith new cascadion clinic mass spec offer ell effort clinic
pleas see earn preview discuss expect quarter detail tool
 dx favor biopharma industri end market diverg d/g
better underli quarterli result thermo fisher rais guidanc account stronger oper
perform show chart compani forecast revenu billion midpoint
billion previous increas upper end low er end
month brammer hich close month advanc bioprocess less anatom patholog divestitur estim
fx headw ind embed guidanc believ would impli midpoint underli organ growth rate
roughli midpoint previou guidanc hich ould consist ith roll organ
grow th quarterli beat guidanc ep project rang y/i versu
estim guidanc midpoint versu previou rang keep mind thermo
fisher guidanc includ capit deploy beyond alreadi announc activ hich includ buy-back
acquisit brammer expect confer call expect question center around
growth biopharma end market execut china out-performance lss data center impact analyt instrument
quarterli growth futur opportun capit deploy
revenu revenu billion came better estim billion grew y/i driven mostli
better organ grow th higher vs model hile fx roughli line vs
model organ growth increas y/i better forecast hile compani origin messag
grow th ould level low ere forecast ith preview account compani data center
outag quarter end hich consist ith compani impact view perform solid context comp
believ biopharma like repres strong driver thermo fisher quarterli out-performance compani
highlight strong perform china addit believ impli analyt instrument organ grow th
headlin adjust segment impact data center highlight compani like continu perform ell
cryo-em mass spectrometri detail thermo fisher uniqu biopharma driver pleas see report
analyst day preview biopharma biz make higher grow th detail biopharma end
market pleas see tool dx biopharma tracker increas nois fundament look solid
adjust oper incom adjust oper incom billion came forecast grew
y/i oper margin improv y/i came expect gross margin ere
low er expect herea sg came better expect revenu
expens revenu ere line ith expect aw ait confer call commentari better understand
driver oper margin line quarter
ep non-gaap ep increas y/i came better estim hich adjust
data center outag better street unclear mani analyst proactiv updat
model compani tax rate expect hile compani share count roughli line
share line item ad quarterli earn
flow capit deploy flow oper billion adjust net incom hile ork
capit strong quarter million gain cash cffo came million expect capital-expenditure
million came forecast repres revenu y/i thermo fisher deploy million
dividend sharehold manag repurchas share quarter come addit activ recent
histori ith recent close acquisit brammer april sale anatom patholog busi june
estim thermo fisher end quarter net debt ttm ebitda give thermo fisher flexibl pursu
acquisit modest repurchas opportun present
life scienc solut total organ growth estim life scienc solut
revenu came expect billion increas y/i stronger organ growth drove revenu beat
thermo fisher bioproduct busi recent area strength compani look confer call see
trend continu quarter currenc roughli headw ind grow th line ith estim
headw ind acquisit bd advanc bioprocess asset ad grow th quarter close segment
oper incom million quarter increas y/i adjust oper margin
 total organ growth estim
revenu increas y/i organ currenc headw ind quarter line ith estim
headw ind describ due data center outag one thermo fisher facil compani experienc overal
headw ind organ grow th delay order process shipment headwind primarili affect analyt
instrument segment impli could headwind segment organ growth context despit
difficult comp organ growth view underli trend healthi expect fei co like help organ
grow th quarter thermo fisher continu complimentari fei co acquisit look confer call
detail integr dynam ithin cycl addit expect share gain continu mass
spec chromatographi pow ere grow th segment acquisit net divestur contribut grow th
quarter segment oper incom decreas y/i million oper margin ere dow y/i
given lost sale increment margin ere surpris see oper incom miss
 specialti diagnost total organ growth estim specialti diagnost
result ere solid though organ revenu came modestli expect organ grow th vs forecast
currenc headw ind quarter line ith estim headw ind report revenu improv rel
model thermo fisher benefit later expect sale compani anatom patholog busi
model headwind growth sale complet quarter adjust oper incom
decreas y/i million oper margin ere dow y/i
laboratori product servic total organ growth estim
laboratori product servic segment revenu came expect quarter ith total revenu increas
y/i organ revenu increas commentari around patheon transact posit look
confer call detail statu integr keep mind patheon transact annual end
august busi contribut fulli organ grow th quarter acquisit brammer ad grow th
quarter close call expect compani provid addit detail initi perform asset
currenc headw ind line ith model adjust ebit increas y/i million oper margin
pleas reach us ith question thank
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens ill
directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog price target repres ebitda estim billion
risk may imped achiev barclay research valuat price agil exposur
econom activ end market hich could impact grow th addit exposur global economi could impact grow th
requir activ dilig cyclic natur agil busi make forecast guidanc rel challeng
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog price target repres ebitda forecast million
risk may imped achiev barclay research valuat price ith long replac cycl
limit consum exposur reliant share gain end market perform drive grow th mettler-
toledo busi model predic end user sale trend tow ard central purchas ould risk food
retail busi ill rel slow grow er manag profit return final ith cyclic core industri
busi sensit advers industri condit
rate price target histori
histor stock price price target may adjust stock split dividend
valuat methodolog price target repres ep estim
risk may imped achiev barclay research valuat price thermo fisher depend
econom grow th end market addit chang foreign exchang rate neg impact revenu
earn grow th final compani recent complet acquisit patheon fei compani carri integr risk
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
